NEXGEL, Inc. (NXGLW) stock
Close on Oct 30, 2026Market cap $34.21MP/E –Yield –
NEXGEL, Inc. grew revenue 3.4% to $12.07M over the twelve months to Jun 30, 2026. Free cash flow was -$1.38M. At the latest close the market valued the company at $34.21M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $34.21M
- P/E ratio
- –
- Price to sales
- 2.84
- Price to book
- 6.91
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $12.07M
- Net income
- -$6.19M
- EPS, diluted
- -$0.71
- Free cash flow
- -$1.38M
- Book value per share
- $0.55
- Diluted shares
- 9M
Trading
- Next earnings
- Nov 11, 2026 (estimated, before the open)
- Previous close
- $0.01
- Open
- $0.01
- Day's range
- $0.01 – $0.01
- Average volume (20 days)
- 32,574
- Beta (5 years)
- 0.61
- 52-week range
- $3.00 – $53.60
- RSI (14 days)
- 38.7
- Volatility (1 year)
- 127.3%
- Relative volume
- 0.74×
- WACC
- 8.0%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | NXGLW | S&P 500 | Difference | NXGLW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.9% | -0.9% | −17.9 pts | ||
| 3 months | -34.9% | +2.1% | −37.0 pts | ||
| Year to date | -95.8% | +11.7% | −107.5 pts | ||
| 1 year | -96.9% | +12.4% | −109.3 pts | ||
| 3 years | -97.1% | +88.6% | −185.6 pts | -69.2% | +23.5% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Nexgel filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- News
- News
- News
About Nexgel
Surgical & Medical Instruments & Apparatus
NexGel, Inc. manufactures custom high-water-content polymer hydrogels using electron-beam cross-linking technology for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It operates as a contract manufacturer supplying bulk gels to third parties, offers custom and white-label manufacturing, and sells branded consumer products. Its consumer brand portfolio includes Medagel over-the-counter remedies, Kenkoderm skincare for psoriasis, and Silly George beauty products. In addition, the business develops medical devices designed to reduce skin irritation, such as its NEXDrape surgical drape and NEXDerm adhesive tape, intending to license them to corporate partners rather than commercializing them directly.
Company profile, executives and historyNexgel stock: common questions
What is Nexgel's stock price?
NXGLW closed at $0.01 on Oct 30, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $3.00 and $53.60.
What is Nexgel's market cap?
Nexgel was worth $34.21M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is NXGLW's P/E ratio?
Nexgel lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.71), so it has no meaningful P/E ratio.
How much revenue does Nexgel make?
Nexgel reported revenue of $12.07M for the twelve months to Jun 30, 2026, up 3.4% from a year earlier.
Does Nexgel pay a dividend?
No. Nexgel has not paid a cash dividend over the last twelve months.
When does Nexgel report earnings next?
Nexgel is expected to report Q3 FY2026 results on Nov 11, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has NXGLW stock performed over the past year?
Including dividends, NXGLW returned -96.9% over the past year, against +12.4% for the S&P 500.
Who are Nexgel's competitors?
Companies most similar to Nexgel by business, industry and size include SNOA, NEPH, SRTS, MDNC, NSPR.